Log in

POSC POSITRON CORP OTC · United States

POSITRON CORP (POSC) news

Latest POSITRON CORP news

  1. Debt Financing

    Positron arranges $2,000,000 line of credit at 12% from investor George Ortiz

    The note matures on August 13, 2028 and bears fixed interest at 12%. Cash is payable only on demand after maturity or while an event of default continues.

POSITRON CORP annual financials

LineFY2025FY2024
Revenue$461,452$587,500
Net income (loss)-$10.6 million-$2.4 million
Cash from operations-$4.7 million-$1.7 million

Latest balance sheet, Sep 30, 2015 (10-Q): cash and equivalents $28,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about POSITRON CORP

What is the ticker symbol of POSITRON CORP?

POSITRON CORP trades under the ticker POSC on OTC.

Where is POSITRON CORP listed?

POSITRON CORP is listed on OTC.

Which country or territory is POSITRON CORP listed under?

Our directory records POSITRON CORP under United States.

Does aibio.space cover POSITRON CORP?

aibio.space lists POSITRON CORP among 2,820 public biotech companies and publishes its news here as stories appear.

What was POSITRON CORP's revenue last year?

$461,452 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is POSITRON CORP profitable?

POSITRON CORP reported a net loss of $10.6 million for the fiscal year ended Dec 31, 2025, and used $4.7 million of cash in operations, per its annual report to the SEC.

How much cash does POSITRON CORP have?

$28,000 in cash at Sep 30, 2015, per its 10-Q.

What is the latest POSITRON CORP (POSC) stock news?

Our latest story on POSITRON CORP, dated Sep 30, 2026: "Positron issues three promissory notes at 20% interest, with warrants". The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share. Source.

Does POSITRON CORP have debt, a term loan or convertible notes?

Our latest debt story, dated Sep 30, 2026: "Positron issues three promissory notes at 20% interest, with warrants". The notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share. Source.

How can I follow POSITRON CORP (POSC) news?

Press Follow on this page to add POSITRON CORP to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming POSITRON CORP so far, in Debt Financing.

Investor discussion: POSITRON CORP

Members talk about POSITRON CORP (POSC). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:POSC on TradingView.

Listing details

POSITRON CORP is a public biotech or pharmaceutical company listed on OTC under the ticker POSC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
POSITRON CORP
Ticker
POSC
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.